Skip to main content
. Author manuscript; available in PMC: 2007 Jun 1.
Published in final edited form as: Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2675–2685. doi: 10.1167/iovs.05-1335

Figure 6.

Figure 6

Changes in clone-YH phenotype with changes in protein glycosylation, illustrated by N-cadherin, with tunicamycin treatment, removal, and recovery. (A) Time line for the tunicamycin treatment protocol and phase contrast phenotype of clone-YH cells. Cells treated with tunicamycin are more epithelioid than untreated cells at the end of the tunicamycin incubation (t = 24 hours) but revert to a fusiform phenotype with recovery after tunicamycin removal (t = 72 hours). Scale bar, 100 μm. (B) Immunoblot of N-cadherin showing deglycosylation after tunicamycin treatment (t = 24 hours) and reglycosylation after removal of tunicamycin and recovery (t = 72 hours).